Skip to content

About Us
Our Science
Partnerships
News

News
READ THE LATEST UPDATES

May 7, 2024 | Press Releases

Inmagene Announces Completion of Enrollment in Phase 2a Trial of IMG-007, a Nondepleting and Half-life Extended Anti-OX40 Monoclonal Antibody, in Patients with Alopecia Areata

May 6, 2024 | Press Releases

Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis

February 3, 2024 | Press Releases

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

4

About Us
Our Science
Partnerships
News

About Us
Our Science
Partnerships
News

Copyright © 2025 Miragene All Rights Reserved

Company

About Us
Our Science
Pipeline
Partnerships
Contact Us

Scroll to Top